BioSpace News Archive

Despite a COVID-19 disease diagnosis, hospitalization and severe outcomes from COVID-19 illness in children and young people with childhood-onset rheumatic diseases were not commonly reported, announced the Childhood Arthritis and Rheumatology Research Alliance (CARRA).

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), today announced that 13 abstracts, including two oral presentations, will be featured at the 2022 American Academy of Neurology (AAN) annual meeting being held April 2-7 in Seattle, WA and virtually from April 24-26.

Tevard Biosciences today announced an agreement to exclusively license “mRNA Amplifier” technology will help form the basis of Tevard’s third platform for addressing diseases in which a mutation has caused a reduction in or loss of a vital protein.

JW Therapeutics announced that it has received the Investigational New Drug clearance from the National Medical Products Administration of China for a pivotal clinical trial of its anti-CD19 autologous chimeric antigen receptor T cell immunotherapy product Carteyva® in the treatment of second-line large B-Cell lymphoma.

Albany NY, United States: Stroke is a medical condition occurs due to interrupted blood supply to the brain, due to blockage of blood vessels which can lead to the death or death of brain cells.

Albany NY, United States: Peptides are mainly made up of amino acid chains which are linked with each other with the peptide bond.

Safety needles can be characterized as an empty bore needle which is considered to decrease or lessen the likelihood of a skin cut harm to the specialist.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2021 on Tuesday, 12 April 2022.

Insud Pharma announced that it has entered into an agreement with Fresenius Kabi.

Airway Therapeutics, Inc. announced dosing of the first patient on March 28, 2022 in the Phase 1b randomized trial of AT-100 for preventative use in very preterm infants at risk for bronchopulmonary dysplasia.